TIAP, previously Mars Innovation, has lured drug firm Amgen to co-invest in portfolio businesses based on its members' health sciences research.

Toronto Innovation Acceleration Partners (TIAP), the Canada-based multi-institution commercialisation firm formerly known as Mars Innovation, entered a co-investment alliance with pharmaceutical firm Amgen on Monday. The partners will jointly fund companies in TIAP’s health sciences portfolio, which builds on research from its 14 member institutions in Ontario. They will also look to identify promising embryonic…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.